Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database

Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis

“…An observational study which included users of SGLT2‐i versus non‐users in two large cohorts did not find an increased risk of AKI in the inpatient setting with SGLT2‐i . Conversely, analysis of the cases reported to the FDA showed an increased risk of AKI with SGLT2‐i versus other glucose‐lowering agents; however, this database is limited by reporting bias …”

Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes

“…Evidence of cardio‐protection from SGLT2 inhibitors relative to other agents has led to a dramatic increase in use of these agents in recent years; thus, our findings are highly relevant as they identify another population‐based risk associated with use of SGLT2 inhibitors that should be carefully weighed against the benefits. While other reported risks associated with use of SGLT2 inhibitors are rare and severe, that is, euglycaemic ketoacidosis, lower limb amputations and acute kidney injury, genital mycotic infections are a common risk with use of SGLT2 inhibitors that affects both women and men.…”

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study

“…Our data are also particularly reassuring on the risk that SGLT2i may acutely worsen renal function. Postmarketing pharmacovigilance has identified cases of acute kidney injury (AKI) in patients taking SGLT2i, probably because of alterations of renal haemodynamics . On the contrary, an observational study comparing 377 SGLT2i users with 377 matched non‐users did not find any association between SGLT2i and AKI .…”